Karyopharm Therapeutics | L'Utile Operativo





L'Utile Operativo Cambiamento Data
AbbVie USD 5.81B 1.23B 2025-12
Abbott USD 2.25B 73M 2025-12
Amgen USD 3.96B 464M 2025-12
AstraZeneca USD -1.5B 5.01B 2025-09
BioCryst Pharmaceuticals USD -2.54M 10.23M 2024-12
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Eli Lilly USD 8.99B 599.9M 2025-12
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Incyte USD 383.88M 47.43M 2025-12
J&J USD 5.59B 1.81B 2025-12
Karyopharm Therapeutics USD -31.28M 5M 2024-12
MacroGenics USD 18.64M 55.4M 2025-09
Merck USD 6.24B 318M 2025-12
Nektar Therapeutics USD -34.34M 15.43M 2024-09
Novartis USD 4.5B 363M 2025-09
Novartis USD 4.58B 879M 2025-09
Pfizer USD 4.65B 3.99B 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Takeda JPY 168.82B 479.89B 2025-12
Tectonic Therapeutic USD -21.89M 440K 2025-09
TG Therapeutics USD 29.36M 5.48M 2025-09
Ultragenyx Pharmaceutical USD -170.89M 22.68M 2025-09
Xencor USD -47.52M 14.35M 2025-09


Karyopharm Therapeutics L'Utile Operativo - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.